+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 80Years
All Genders
ID06798415

Study of Intralesional Metronidazole Injection to Treat Cutaneous Leishmaniasis Lesions in Adults

Led by Hayder Adnan Fawzi · Updated on 2025-02-14

40

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the use of intralesional metronidazole 0.5% solution as a local injection to treat cutaneous leishmaniasis. This open-label, single-arm phase 2 trial aims to evaluate the cure rate of cutaneous leishmaniasis lesions following this treatment. The study focuses on patients with one or multiple skin lesions caused by this condition. Participants will receive intralesional metronidazole injections based on lesion size, with a dose of 5 mg per cm2, using a fine insulin needle. The treatment is administered once weekly for up to 6 weeks, but if lesions heal earlier, treatment will stop and only assessments will continue. Each lesion is treated individually and followed for up to 90 days or until cured. During the study, patients will have their lesions monitored regularly to assess healing. Researchers will measure the cure rate from enrollment through treatment and follow-up. No local anesthesia is used during injections, and the volume injected varies by lesion size. Participants can expect weekly visits for up to 6 weeks for treatment and additional follow-ups until 90 days after starting treatment.

CONDITIONS

Brief Title

Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis

Research Team

H

Hayder Adnan Fawzi, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here